Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Transdermal Drug Patches to 2024" report to their offering.
Transdermal drug patches to 2024 analyzes products, markets and commercialization factors for drug patches. The report examines the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver.
Advances in synthetic materials and patch design have led to patches that are more aesthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors - factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2024.
What You Will Learn
- What are the current transdermal drug patch markets and products, and what is the market potential for existing and probable future products?
- What is the impact of patch designs, technologies and patch development issues on commercialization?
- Who are the leading patch manufacturers and third-party transdermal supply chain companies?
- What is the current product and competitive landscape, and what are the details of the numerous products across the various patch product categories and markets?
- What is the size of the market now, and how will it change in the next seven years to 2024?
- Who are the transdermal drug patch product providers, and what are their product development activity, and strategies?
- What is the market impact of economic, technology, and regulatory factors?
Key Topics Covered:
1. Executive Summary
2. The Market Opportunity
- Transdermal Drug Delivery Dynamics
- Demand Drivers
- Competitive Landscape
- Factors Limiting Growth
- Pharmacokinetics & Dosage Forms
- Patch Manufacturing Dynamics
- Patch Manufacturing Company Profiles
3. Product Analysis - FDA-Approved Drugs Delivered via Transdermal Patches
- Alkaloids
- Androgens
- Antidepressants
- Antiemetics
- Antispasmodics
- CNS Stimulants
- Cholinesterase Inhibitors
- Dopamine Agonists
- Hormone Replacement
- Hypotensive Agents
- Local Anesthetics
- NSAIDs
- Opioid Analgesics
- Progestrins
- Trinitrates
4. Development-stage Drug Patches
5. Market Analysis - Transdermal Drug Patch Therapeutics
- ADHD
- Addiction
- Contraception
- Cardiovascular/Angina
- Depression
- Hormone Replacement Therapy
- Hypertension
- Motion Sickness
- Neurology
- Osteoporosis
- Pain Management
6. Market Factors
- Regulatory Issues
- IP and Expiring Patents
- Rx-to-OTC Switching
- Patient Compliance and Ease of Use
- Healthcare Economics
7. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/b4bn3l/transdermal_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Transdermal and Transmucosal Drug Delivery


NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 



